Bone Matrix Proteoglycans in Skeletal Function - Osteogenesis Imperfecta - page 88

mediates commitment of MC3T3-E1 cells toward osteogenesis.
J Cell Physiol 2009;220(3):780-91.

[135] Solheim K. Osteogenesis imperfecta. Microradiographic and bio-

chemical studies with special reference to the mucopolysaccha-
rides (glycosaminoglycans). J Oslo City Hosp 1969;19(12):193-9. [128] Viviano BL, Silverstein L, Plederer C, Paine-Saunders S, Mills K,

Saunders S. Altered hematopoiesis in glypican-3-deicient mice
results in decreased osteoclast differentiation and a delay in
endochondral ossiication. Dev Biol 2005;282(1):152-62.

[136] Vetter U, Fisher LW, Mintz KP, Kopp JB, Tuross N, Termine JD,

et al. Osteogenesis imperfecta: changes in noncollagenous pro-
teins in bone. J Bone Miner Res 1991;6(5):501-5.

[129] Campos-Xavier AB, Martinet D, Bateman J, Belluoccio D, Rowley

L, Tan TY, et al. Mutations in the heparan-sulfate proteoglycan
glypican 6 (GPC6) impair endochondral ossiication and cause
recessive omodysplasia. Am J Hum Genet 2009;84(6):760-70.

[137] Sarathchandra P, Pope FM, Ali SY. An ultrastructural and

immunogold localization study of proteoglycans associated
with the osteocytes of fetal bone in osteogenesis imperfecta.
Calcif Tissue Int 1996;58(6):435-42.

[130] Cano-Gauci DF, Song HH, Yang H, McKerlie C, Choo B, Shi W,

et al. Glypican-3-deicient mice exhibit developmental over-
growth and some of the abnormalities typical of Simpson-
Golabi-Behmel syndrome. J Cell Biol 1999;146(1):255-64.

[138] McCormick C, Leduc Y, Martindale D, Mattison K, Esford

LE, Dyer AP, et al. The putative tumour suppressor EXT1
alters the expression of cell-surface heparan sulfate. Nat Genet
1998;19(2):158-61.

[131] Pilia G, Hughes-Benzie RM, MacKenzie A, Baybayan P, Chen

EY, Huber R, et al. Mutations in GPC3, a glypican gene, cause
the Simpson-Golabi-Behmel overgrowth syndrome. Nat Genet
1996;12(3):241-7.

[139] Ahn J, Ludecke HJ, Lindow S, Horton WA, Lee B, Wagner MJ,

et al. Cloning of the putative tumour suppressor gene for heredi-
tary multiple exostoses (EXT1). Nat Genet 1995;11(2):137-43.

[140] Stickens D, Clines G, Burbee D, Ramos P, Thomas S, Hogue

D, et al. The EXT2 multiple exostoses gene deines a family of
putative tumour suppressor genes. Nat Genet 1996;14(1):25-32.

[132] Marini JC, Forlino A, Cabral WA, Barnes AM, San Antonio

JD, Milgrom S, et al. Consortium for osteogenesis imperfecta
mutations in the helical domain of type I collagen: regions rich
in lethal mutations align with collagen binding sites for integ-
rins and proteoglycans. Hum Mutat 2007;28(3):209-21.

[141] Vlodavsky I, Friedmann Y, Elkin M, Aingorn H, Atzmon R,

Ishai-Michaeli R, et al. Mammalian heparanase: gene cloning,
expression and function in tumor progression and metastasis.
Nat Med 1999;5(7):793-802. [133] Dyne KM, Valli M, Forlino A, Mottes M, Kresse H, Cetta G.

Deicient expression of the small proteoglycan decorin in a
case of severe/lethal osteogenesis imperfecta. Am J Med Genet
1996;63(1):161-6.

[142] Kram V, Zcharia E, Yacoby-Zeevi O, Metzger S, Chajek-Shaul T,

Gabet Y, et al. Heparanase is expressed in osteoblastic cells and
stimulates bone formation and bone mass. J Cell Physiol 2006;
207(3):784-92. [134] Engfeldt B, Hjerpe A. Glycosaminoglycans of cartilage and

bone tissue in two cases of osteogenesis imperfecta congenita.
Acta Pathol Microbiol Scand [A] 1976;84(6):488-94.